Perspectives in renal disease progression: The endothelium as a treatment target in chronic kidney disease

Journal of Nephrology

Volumn 23, Issue 4, 2010, Pages 369-376

  Fliser, Danilo ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Asymmetric dimethylarginine (ADMA); Chronic kidney disease (CKD); Endothelium; Erythropoietin (EPO); Progression

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DIMETHYLARGININASE; ERYTHROPOIETIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; AMIDASE; ARGININE; N,N-DIMETHYLARGININE; RECOMBINANT PROTEIN;

ANEMIA; BLOOD LEVEL; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR RISK; CELL FUNCTION; CELL PROTECTION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ERYTHROPOIESIS; HEMATOCRIT; HEMATOPOIETIC CELL; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOXEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY MEDULLA; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; RENAL PROTECTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; VASOMOTOR REFLEX; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC DISEASE; DRUG EFFECTS; KIDNEY DISEASES; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

AMIDOHYDROLASES; ARGININE; CHRONIC DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HUMANS; KIDNEY DISEASES; NITRIC OXIDE SYNTHASE; RECOMBINANT PROTEINS;

EID: 77955457090     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Aird WC. Phenotypic heterogeneity of the endothelium: Part I: structure, function, and mechanisms. Circ Res. 2007;100:158-173.
2. Aird WC. Phenotypic heterogeneity of the endothelium: Part II: representative vascular beds. Circ Res. 2007;100:173-190.
3. Kang DK, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806-816.
4. Kang DK, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol. 2002;161:239-248. (Pubitemid 34760789)
5. Fliser D, De Groot K, Bahlmann FH, Haller H. Mechanisms of disease: erythropoietin - an old hormone with a new mission? Nat Clin Pract Cardiovasc Med. 2006;3:563-572.
6. Kielstein JT, Fliser D. The past, presence and future of ADMA in Nephrology. Nephrol Ther. 2007;3:47-54.
7. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, et al. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant. 2002;17:1999-2002.
8. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol. 1994;112:43-48. (Pubitemid 24151701)
9. Yilmaz MI, Sonmez A, Saglam M, et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol. 2008;19:388-395.
10. Leiper JM, Santa MJ, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343:209-214.
11. Tanaka M, Sydow K, Gunawan F, et al. DDAH overexpression suppresses graft coronary artery disease. Circulation. 2005;112:1549-1556.
12. Jacobi J, Sydow K, von DG et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation. 2005;111:1431-1438.
13. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13:198-203.
14. Segarra G, Medina P, Ballester RM, et al. Effects of some guanidino compounds on human cerebral arteries. Stroke. 1999;30:2206-2210. (Pubitemid 29473272)
15. Segarra G, Medina P, Vila JM, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens. 2001;14:1142-1148.
16. Gardiner SM, Kemp PA, Bennett T, et al. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol. 1993;110:145714-145764.
17. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172-177. (Pubitemid 38114135)
18. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-1459. (Pubitemid 36994536)
19. Kielstein JT, Simmel S, Bode-Boger SM, et al. Subpressor dose asymmetric dimethylarginine (ADMA) modulates renal function in humans. Kidney Blood Press Res. 2004;27:143-147.
20. Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke. 2006;37:2024-2029. (Pubitemid 44309898)
21. Veresh Z, Racz A, Lotz G, Koller A. ADMA impairs nitric oxide- mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Hypertension. 2008;52:960-966.
22. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24:1682-1688.
23. Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30:1142-1150.
24. Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296:R195-R200.
25. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol. 2005;46:1693-1701.
26. Chirinos JA, David R, Bralley JA, et al. Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease. The PREVENCION Study. Hypertension. 2008;52:1051-1059.
27. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62:339-345.
28. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-2117.
29. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007;53:273-283. (Pubitemid 46338272)
30. Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592-1600.
31. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
32. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002;13:170-176.
33. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005;16:2456-2461. (Pubitemid 41725064)
34. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005;16:2449-2455.
35. Lajer M, Tarnow L, Jorsal A, et al. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2008;31:747-752.
36. Hanai K, Babazono T, Nyumura I, et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant. 2009;24:1884-1888.
37. Matsumoto Y, Ueda S, Yamagishi S, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol. 2007;18:1525-1533.
38. Shibata R, Ueda S, Yamagishi S, et al. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol Dial Transplant. 2009;24:1162-1169.
39. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II subtype 1-receptor inhibition reduces (intra)renal vascular resistance in patients with type 2 diabetes mellitus. J Am Soc Nephrol. 2005;16:1135-1140.
40. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006;70:2109-2115. (Pubitemid 44871373)
41. Wojchowski DM, Gregory RC, Miller CP, et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res. 1999;253:143-156.
42. Datta SR, Dudek H, Tao X, et al. AKT phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
43. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87:5978-5982.
44. Carlini RG, Alonzo EJ, Dominguez J, et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int. 1999;55:546-553. (Pubitemid 29082880)
45. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93:2627-2636.
46. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of AKT1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106:2973-2979.
47. Beleslin-Cokic BB, Cokic VP, Yu X, et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004;104:2073-2080.
48. d'Uscio LV, Smith LA, Santhanam AV, et al. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension. 2007;49:1142-1148.
49. Dzau VJ, Gnecchi M, Pachori AS, et al. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension. 2005;46:7-18.
50. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103:921-926.
51. Bahlmann FH, deGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003;64:1648-1652.
52. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340-1346. (Pubitemid 36988041)
53. Urao N, Okigaki M, Yamada H, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via AKT-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res. 2006;98:1405-1413.
54. Westenbrink BD, Lipsic E, van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007;28:2018-2027.
55. Rossert J, Froissart M. Role of anemia in progression of chronic kidney disease. Semin Nephrol. 2006;26:283-289.
56. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753-760.
57. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176-185. (Pubitemid 27440408)
58. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
59. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
60. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial AKT and attenuates progressive organ failure. Circulation. 2004;100:1006-1012.
61. Fliser D, Bahlmann FH, Haller H. EPO: renoprotection beyond anemia correction. Pediatr Nephrol. 2006;21:1785-1789. (Pubitemid 44741154)
62. Menne J, Park JK, Shushakova N, et al. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol. 2007;18:2046-2053.
63. Eto N, Wada T, Inagi R, et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int. 2007;72:455-463.
64. Katavetin P, Inagi R, Miyata T, et al. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem Biophys Res Commun. 2007;359:928-934.
65. Logar CM, Brinkkoetter PT, Krofft RD, et al. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int. 2007;72:489-498.
66. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-2989.
67. Lindenblatt N, Menger MD, Klar E, Vollmar B. Darbepoetinalpha does not promote microvascular thrombus formation in mice: role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol. 2007;27:1191-1198.
68. Coleman TR, Westenfelder C, Tögel FE, et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A. 2006;103:5965-5970.